Article Text

Download PDFPDF
Accumulating evidence supports advanced bronchoscopy as a modality of choice for difficult-to-reach peripheral lung nodules, but questions remain
  1. Rafael Paez,
  2. Fabien Maldonado
  1. Vanderbilt University Medical Center, Nashville, Tennessee, USA
  1. Correspondence to Dr Fabien Maldonado; fabien.maldonado{at}vumc.org

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Despite significant advances in the last decade, lung cancer remains the leading cause of cancer-related deaths, and early detection and diagnosis are paramount.1 Oftentimes, early lung cancer presents as a small nodule detected on a CT scan either incidentally or through lung cancer screening.2 3 Further evaluation of these nodules depends on radiographic characteristics, such as size, morphology and location, and individual risk factors, such as age and smoking history. Nodules at intermediate or high probability of malignancy are often referred for additional testing, including biopsy, which traditionally has been done via CT-guided transthoracic needle biopsy. Over the last decade, advanced diagnostic bronchoscopy has emerged as a reasonable alternative, with a recent randomised controlled trial suggesting comparable diagnostic yield.4 5

The study by Fernandez–Bussy and colleagues published in the journal is a two-centre retrospective study of 182 lung nodules biopsied using shape-sensing robotic-assisted bronchoscopy with intraprocedural mobile cone beam CT guidance. Notably, these nodules were either abutting the pleura or perifissural, which traditionally have been thought to carry a higher risk of procedural complications and are more difficult to reach via bronchoscopy. In this selected population, the authors report a notable diagnostic …

View Full Text

Footnotes

  • Contributors FM and RP contributed substantially to writing the manuscript. FM is the guarantor of the content of the manuscript.

  • Funding Pierre Massion Directorship in Lung Cancer Research (no grant number) and Division of Cancer Prevention, National Cancer Institute 1R01CA253923 (FM)

  • Competing interests FM reports speaking fees, education payments and travel/lodging payments from Intuitive; speaking fees and associated research funding from Medtronic; and consulting fees from Johnson & Johnson. RP reports consulting fees from Noah Medical.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles